Krystal Biotech (KRYS) Research & Development (2016 - 2026)

Krystal Biotech has disclosed Research & Development across 11 years of filings, most recently posting $15.3 million for Q1 2026.

• Research & Development for Q1 2026 came in at $15.3 million, up 7.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $59.1 million (up 3.94% YoY), and the FY2025 annual result was $58.0 million, up 8.33% from the prior year.
• Research & Development came in at $15.3 million for Q1 2026 at Krystal Biotech, up from $14.8 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $15.6 million in Q2 2024 to a low of $9.3 million in Q1 2022.
• The 5-year median for Research & Development is $12.3 million (2023), against an average of $12.7 million.
• Across the five-year window, Research & Development jumped 89.41% in 2022 and slipped 10.83% in 2024, its largest moves.
• Krystal Biotech's Research & Development stood at $10.7 million in 2022, then climbed by 5.87% to $11.4 million in 2023, then advanced by 18.96% to $13.5 million in 2024, then advanced by 9.36% to $14.8 million in 2025, then grew by 3.63% to $15.3 million in 2026.
• The last three Research & Development figures came in at $15.3 million (Q1 2026), $14.8 million (Q4 2025), and $14.6 million (Q3 2025), per Business Quant data.